Introducing Myriad myPath® Melanoma

A unique clinically validated molecular assay created specifically to assist physicians in differentiating malignant melanoma from benign nevi in difficult to diagnose melanocytic lesions. By analyzing 23 genes using qRT-PCR technology, this assay provides objective, additive diagnostic information.

To join the Clinical Experience Program, click on the Get Involved link at the top of the page